At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05018845Phase 1RecruitingUpdate OverdueUpdated 14mo ago · Completion was 7mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Chronic Kidney Disease.
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Aug 24, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Chronic Kidney Diseases. Currently recruiting, targeting 20 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Chronic Kidney Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases
CountriesAntigua and Barbuda
Collaborators--
Timeline
Phase 1RecruitingOverdue
20222023202420252026
First PostedAug 2021
Enrollment StartNov 2021
Primary CompletionNov 2025
TodayJul 2026
First PostedAug 24, 2021
Enrollment StartNov 6, 2021
Primary CompletionNov 1, 2025
TodayJul 1, 2026
Enrollment to primary: 4.0 yearsPosted 4.9 years ago
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells